1313195-84-4
1313195-84-4
Chemical Structure
WO-459
- CAS No.: 1313195-84-4
- Formula:C23H20F3N3O2S
- Molecular Weight:459.48
InChIKey: OOXRLZNAKGXYGI-UHFFFAOYSA-N
SMILES: O=C(C1=CN(C2=CC=CC3=C2SC(CC4=CC=CC(C(F)(F)F)=C4)=C3)N=C1C)NCCO
Biological Activity: WO-459 is a potent Gpr52 agonist. WO-459 induces dose-dependent elevation of intracellular cAMP in cells expressing Gpr52. WO-459 can be used for the research of Huntington’s disease and psychotic disorders[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
WO-459 | WO-459 is a potent Gpr52 agonist. WO-459 induces dose-dependent elevation of intracellular cAMP in cells expressing Gpr52. WO-459 can be used for the research of Huntington’s disease and psychotic disorders. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Nakahata T, et al. Design and synthesis of 1-(1-benzothiophen-7-yl)-1H-pyrazole, a novel series of G protein-coupled receptor 52 (GPR52) agonists. Bioorg Med Chem. 2018 May 1;26(8):1598-1608. [Content Brief]
- [2]. Song H, et al. Targeting Gpr52 lowers mutant HTT levels and rescues Huntington's disease-associated phenotypes. Brain. 2018;141(6):1782-1798. [Content Brief]
